MarketPulse

hidradenitis suppurativa

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Avalo Therapeutics Raises $375M to Advance Hidradenitis Suppurativa Treatment

Avalo Therapeutics prices $375M offering of 19.73M shares at $17.75 each to fund Phase 3 development of hidradenitis suppurativa treatment abdakibart, closing May 7, 2026.
AVTXPhase 3 clinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Moonlake Immunotherapeutics

MoonLake's Sonelokimab Sustains Strong Phase 3 Results in Hidradenitis Suppurativa

MoonLake reports Week 40 Phase 3 data for sonelokimab showing 62% HiSCR75 response rates in hidradenitis suppurativa with no new safety signals.
MLTXPhase 3 clinical trialquality of life
GlobeNewswire Inc.GlobeNewswire Inc.··Novartis

Novartis Showcases Dermatology Pipeline Momentum With Early-Relief Data at AAD 2026

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.
NVSchronic spontaneous urticariaimmunology
BenzingaBenzinga··Vandana Singh

Novartis Expands Cosentyx Reach Into Pediatric Dermatology With FDA Approval

Novartis wins FDA approval for Cosentyx in pediatric hidradenitis suppurativa patients aged 12+, marking the drug's fourth pediatric indication and expanding its dermatology portfolio.
NVSFDA approvalautoimmune disease